Efficacy improvement of chimeric antigen receptor T-cell immunotherapy: reports from the 57th American Society of Hematology annual meeting / 白血病·淋巴瘤

How to improve the efficacy of chimeric antigen receptor T-cell (CAR-T) is one of the key points for manufacture and application of CAR-T. In this review, the studies from the 57th American Society of Hematology (ASH) annual meeting regarding to the strategies for optimal CAR-T activity were summarized, including pathway inhibitors, enhancement antigen expression of target cells, optimization of conditioning chemotherapy, as well as the novel technology for CAR-T generation.

Application and resistance mechanism of B-cell receptor signaling pathway inhibitors in lymphoma:reports from the 57th American Society of Hematology annual meeting / 白血病·淋巴瘤

With the recent success of B-cell receptor (BCR) signaling pathway inhibitor in the treatment of patients with relapsed or refractory non-Hodgkin lymphoma (NHL), a number of new agents targeting the BCR signaling pathway are in a clinical research stage. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. Studies have also found the drug resistance of BCR signaling pathway inhibitors, drawing attention of the mechanism and the way to overcome the drug resistance. Combined with the research progress reported in 57th American Society of Hematology (ASH) annual meeting, this article summarized the recent progress of BCR signaling pathway inhibitors and their resistance mechanism to provide new information on clinical therapy.